Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: Analysis of the National Cancer Database

JAMA Oncology

Volumn 3, Issue 1, 2017, Pages 76-82

  Rauh Hain, J Alejandro ^a   Melamed, Alexander ^c   Wright, Alexi ^a   Gockley, Allison ^a   Clemmer, Joel T ^a   Schorge, John O ^a   Del Carmen, Marcela G ^a   Keating, Nancy L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CYTOREDUCTIVE SURGERY; DATA BASE; DISEASE ASSOCIATION; DISEASE BURDEN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PREVALENCE; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; UNITED STATES; YOUNG ADULT; DISEASE FREE SURVIVAL; FACTUAL DATABASE; KAPLAN MEIER METHOD; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85013076618     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.4411     Document Type: Article

References (32)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519-2529.
2. Vergote I, Tropé CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953.
3. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-257.
4. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al; National Comprehensive Cancer Network. Ovarian cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4(9):912-939.
5. Worley MJ Jr, Guseh SH, Rauh-Hain JA, et al. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014;211(3):231.e1-231.e9.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
7. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083-1090.
8. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47(2):159-166.
9. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77-85.
10. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1): 26-31.
11. Schorge JO, Clark RM, Lee SI, Penson RT. Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol Oncol. 2014;135(3):595-605.
12. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol. 2011;29(31):4073-4075.
13. van Meurs HS, Tajik P, Hof MH, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? an exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013;49(15):3191-3201.
14. Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99(8): 488-490.
15. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12):1258-1267.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
17. Winchester DP, Stewart AK, Phillips JL, Ward EE. The National Cancer Data Base: past, present, and future. Ann Surg Oncol. 2010;17(1):4-7.
18. Mallin K, Palis BE, Watroba N, et al. Completeness of American cancer registry treatment data: implications for quality of care research. J Am Coll Surg. 2013;216(3):428-437.
19. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983a;70:41-55.
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
21. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010; 118(3):262-267.
22. Bristow RE, Puri I, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Analysis of contemporary trends in access to high-volume ovarian cancer surgical care. Ann Surg Oncol. 2009;16(12):3422-3430.
23. Rosenbaum PR, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcomes. J R Stat Soc [Ser A]. 1983;45:212-218.
24. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54(3):948-963.
25. Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33 (8):937-943.
26. Teramukai S, Ochiai K, Tada H, Fukushima M; Japan Multinational Trial Organization OC01-01. PIEPOC: a new prognostic index for advanced epithelial ovarian cancer—Japan Multinational Trial Organization OC01-01. J Clin Oncol. 2007;25(22): 3302-3306.
27. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20-25.
28. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104(2):480-490.
29. Lin JJ, Egorova N, Franco R, Prasad-Hayes M, Bickell NA. Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995-2008. Obstet Gynecol. 2016;127(1):81-89.
30. Wright JD, Ananth CV, Tsui J, et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer. 2014; 120(8):1246-1254.
31. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol. 2010;119(1):18-21.
32. Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer. 2012;22(3):407-416.